Full Press Release Details
Opus Genetics Announces Financial Results for
Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -
- FDA grants Regenerative Medicine Advanced Therapy (RMAT)
designation for OPGx-LCA5 -
- Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% -
- OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease -
- Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs -
RESEARCH TRIANGLE PARK, N.C. - August 13, 2025 - Opus Genetics, Inc. (Nasdaq: IRD) (the "Company" or "Opus
Genetics"), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders,
today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update.
"We've made significant progress across our pipeline, with multiple clinical and regulatory milestones achieved this quarter," said George Magrath, M.D., Chief Executive
Officer, Opus Genetics. "Receiving RMAT designation for our OPGx-LCA5 program underscores the strength of our clinical data and the urgent need for effective gene therapies to treat inherited retinal diseases. We are encouraged by the sustained
functional vision improvements observed in adult patients in our clinical trial to date and the early signs of efficacy in the pediatric cohort. In parallel, our advancement of OPGx-BEST1 toward the clinic and the nomination of two additional
development candidates in partnership with the Retinal Degeneration Fund and the Global RDH12 Alliance highlight the breadth of our IRD pipeline."
"Beyond gene therapy, the positive readouts from our two Phase 3 Phentolamine trials represent a major step toward our goal of bringing a new treatment option to millions
of patients living with vision challenges. With several upcoming key milestones, including new clinical data, a supplemental New Drug Application (sNDA) submission, and the launch of a pivotal study, we remain focused on execution to deliver
transformative treatments to patients with significant unmet needs," Dr. Magrath concluded.
OPGx-LCA5 - Gene Therapy for Leber Congenital Amaurosis (LCA)
OPGx-BEST1 - Gene Therapy for BEST1-Related IRD
OPGx-RDH12 and OPGx-MERTK - Advancing with Non-Dilutive Support
Phentolamine Ophthalmic Solution 0.75% - Advancing Toward sNDA Submissions
Additional Medical Meeting Presentations
Upcoming Expected Data Readouts and Program Advancements
Financial Results for the Second Quarter Ended June 30, 2025
Cash Position: As of June 30, 2025, Opus Genetics
had cash and cash equivalents of $32.4 million. Based on current operating plans, the Company expects its existing cash resources will fund operations into the second half of 2026.
Revenue: License and collaboration revenue totaled
$2.9 million for the second quarter of 2025, compared to $1.1 million in the same period in 2024. Revenue in both periods was driven by the Company's collaboration with Viatris, Inc., primarily from reimbursement of R&D services.
General and Administrative (G&A) Expenses:
G&A expenses were $5.8 million for the second quarter of 2025, compared to $3.4 million for the same period in 2024. The increase was mainly due to higher costs associated with legal and patent-related expenses, payroll, and business
development activities. G&A expenses included $0.6 million and $0.5 million in stock-based compensation in the second quarters of 2025 and 2024, respectively.
Research and Development (R&D) Expenses: R&D
expenses were $6.0 million for the second quarter of 2025, compared to $6.1 million in the prior-year period. The slight decrease was primarily due to lower manufacturing and consulting costs, partially offset by increased clinical trial,
toxicology, and payroll-related expenses. R&D expenses related to Phentolamine Ophthalmic Solution 0.75% were fully reimbursed under the Viatris License Agreement. Stock-based compensation within R&D expenses was $0.3 million in both
Net Loss: Net loss for the second quarter of 2025
was $7.4 million, or $(0.12) per basic and diluted share, compared to a net loss of $7.8 million, or $(0.30) per basic and diluted share, for the second quarter of 2024.
SEC Filing: Additional details on the Company's
financial results will be available in its Quarterly Report on Form 10-Q for the period ended June 30, 2025, to be filed with the U.S. Securities and Exchange Commission (SEC).
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies
for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are
OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently
approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in
Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not
limited to, statements related to cash runway, the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations
regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially
from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading "Risk Factors" included in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press
release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "aim,"
"may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to
revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
IR Advisory Solutions
-Financial Tables Follow-
Condensed Consolidated Balance Sheets
(in thousands, except share amounts and par value)
| As of | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| Assets | (Unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 32,429 | $ | 30,321 | ||||
| Accounts receivable | 3,399 | 3,563 | ||||||
| Contract assets and unbilled receivables | 1,178 | 2,209 | ||||||
| Prepaids and other current assets | 1,433 | 515 | ||||||
| Short-term investments | - | 2 | ||||||
| Total current assets | 38,439 | 36,610 | ||||||
| Property and equipment, net | 226 | 252 | ||||||
| Total assets | $ | 38,665 | $ | 36,862 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,465 | $ | 3,148 | ||||
| Accrued expenses and other liabilities | 6,927 | 8,147 | ||||||
| Warrant liabilities | 11,800 | - | ||||||
| Total current liabilities | 20,192 | 11,295 | ||||||
| Long-term funding agreement, related party | 1,000 | - | ||||||
| Total liabilities | 21,192 | 11,295 | ||||||
| Commitments and contingencies | ||||||||
| Series A preferred stock, par value $0.0001; 14,146 shares were designated as of June 30, 2025 and December 31, 2024; zero and 14,145.374 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. | - | 18,843 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock, par value $0.0001; 9,985,854 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024. | - | - | ||||||
| Common stock, par value $0.0001; 125,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 59,908,055 and 31,574,657 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. | 6 | 3 | ||||||
| Additional paid-in capital | 172,079 | 145,719 | ||||||
| Accumulated deficit | (154,612 | ) | (138,998 | ) | ||||
| Total stockholders' equity | 17,473 | 6,724 | ||||||
| Total liabilities, series A preferred stock and stockholders' equity | $ | 38,665 | $ | 36,862 |
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share amounts)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| License and collaborations revenue | $ | 2,882 | $ | 1,112 | $ | 7,252 | $ | 2,823 | ||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | 5,766 | 3,354 | 12,112 | 8,024 | ||||||||||||
| Research and development | 6,022 | 6,086 | 13,975 | 10,835 | ||||||||||||
| Total operating expenses | 11,788 | 9,440 | 26,087 | 18,859 | ||||||||||||
| Loss from operations | (8,906 | ) | (8,328 | ) | (18,835 | ) | (16,036 | ) | ||||||||
| Fair value change in warrant and other derivative liabilities | 917 | - | 3,722 | - | ||||||||||||
| Financing costs | 35 | - | (1,337 | ) | - | |||||||||||
| Other income, net | 534 | 563 | 836 | 1,165 | ||||||||||||
| Loss before income taxes | (7,420 | ) | (7,765 | ) | (15,614 | ) | (14,871 | ) | ||||||||
| Benefit (provision) for income taxes | - | - | - | - | ||||||||||||
| Net loss | (7,420 | ) | (7,765 | ) | (15,614 | ) | (14,871 | ) | ||||||||
| Other comprehensive loss, net of tax | - | - | ||||||||||||||
| Comprehensive loss | $ | (7,420 | ) | $ | (7,765 | ) | $ | (15,614 | ) | $ | (14,871 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.12 | ) | $ | (0.30 | ) | $ | (0.32 | ) | $ | (0.59 | ) | ||||
| Number of shares used in per share calculations: | ||||||||||||||||
| Basic and diluted | 63,376,392 | 25,827,265 | 48,712,124 | 25,175,596 |
Source: Opus Genetics, Inc.